Initial bone marrow aspiration in childhood idiopathic thrombocytopenia: Decision analysis

American Journal of Pediatric Hematology/Oncology

Volumn 23, Issue 8, 2001, Pages 511-518

  Klaassen, Robert J ^a   Doyle, John J ^b   Krahn, Murray D ^c,d   Blanchette, Victor S ^b   Naglie, Gary ^c,d  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bone marrow examination; Decision support techniques; Health status indicators; Idiopathic; Immunoglobulins; Intravenous; Leukemia; Life expectancy; Prednisone; Purpura; Quality of life; Sensitivity; Specificity; Thrombocytopenic

Indexed keywords

CORTICOSTEROID; HEMOGLOBIN;

ADOLESCENT; ADULT; ALGORITHM; ARTICLE; BLOOD SMEAR; BONE MARROW BIOPSY; CHILD; DIAGNOSTIC VALUE; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFANT; LEUKOCYTE COUNT; LIFE EXPECTANCY; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTE COUNT; TREATMENT PLANNING;

ADOLESCENT; BIOPSY, NEEDLE; BONE MARROW; BONE MARROW EXAMINATION; CHILD; CHILD, PRESCHOOL; DECISION SUPPORT TECHNIQUES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEALTH STATUS INDICATORS; HUMANS; INFANT; LEUKEMIA; LIFE EXPECTANCY; MALE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; QUALITY OF LIFE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 0035203190     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200111000-00009     Document Type: Article

References (40)

1. Lilleyman JS. Intracranial hemorrhage in idiopathic thrombocytopenic purpura. Paediatric Haematology Forum of the British Society for Haematology. Arch Dis Child 1994; 71: 251-3.
2. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology (see comments). Blood 1996; 88: 3-40.
3. Blanchette V, Imbach P, Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994; 344: 703-7.
4. Arico M, Basso G, Mandelli F, et al. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Cancer 1995; 75: 1684-93.
5. Epstein JS, Zoon KC. Letter. Food and Drug Administration, Department of Health and Human Services, Public Health Service, U.S.A., January 1998.
6. Bjoro K, Froland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin (see comments). N Engl J Med 1994; 331: 1607-11.
7. Gera R, Kulkarni R, Scott-Emuakpor A. Transient acute renal failure (ARF) and anti-D intravascular hemolysis (IVH) following intravenous (IV) treatment of immune thrombocytopenia (ITP). J Pediatr Hematol Oncol 2000; 22: 372.
8. Vesely S, Buchanan GR, Cohen A, et al. Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: results of a survey of practicing pediatric hematology/oncology specialists. J Pediatr Hematol Oncol 2000; 22: 55-61.
9. Eden OB, Lilleyman JS. Guidelines for management of idiopathic thrombocytopenic purpura. The British Paediatric Haematology Group. Arch Dis Child 1992; 67: 1056-8.
10. Calpin C, Dick P, Poon A, et al. Is bone marrow aspiration needed in acute childhood idiopathic thrombocytopenic purpura to rule out leukemia? Arch Pediatr Adolesc Med 1998; 152: 345-7.
11. Dubansky AS, Boyett JM, Falletta J, et al. Isolated thrombocytopenia in children with acute lymphoblastic leukemia: a rare event in a Pediatric Oncology Group Study. Pediatrics 1989; 84: 1068-71.
12. Dallal GE. Pc-size: A program for sample size determinations. The American Statistician 1986; 40: 52.
13. Disch DL, Greenberg ML, Holzberger PT, et al. Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. Ann Intern Med 1994; 120: 449-57.
14. Blanchette VS, Luke B, Andrew M, et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993; 123: 989-95.
15. Health Indicators. [CD-ROM] 82-221-XDE ed. Statistics Canada, 1996.
16. Halperin DS, Doyle JJ. Is bone marrow examination justified in idiopathic thrombocytopenic purpura? Am J Dis Child 1988; 142: 508-11.
17. Pollock BH, DeBaun MR, Camitta BM, et al. Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 2000; 18: 813-23.
18. Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet 1995; 345: 143-8.
19. Cherlow JM, Sather H, Steinherz P, et al. Craniospinal irradiation for acute lymphoblastic leukemia with central nervous system disease at diagnosis: a report from the Children’s Cancer Group. Int J Radiat Oncol Biol Phys 1996; 36: 19-27.
20. Reid MM. Bone marrow examination before steroids in thrombocytopenic purpura or arthritis. Acta Paediatr 1992; 81: 1052-3.
21. Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997; 90: 1009-13.
22. Clausen N, Kreuger A, Salmi T, et al. Severe aplastic anaemia in the Nordic countries: a population based study of incidence, presentation, course, and outcome. Arch Dis Child 1996; 74: 319-22.
23. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000; 160: 1630-8.
24. Laxenaire MC, Moneret-Vautrin DA, Boileau S, et al. Adverse reactions to intravenous agents in anesthesia in France. Klin Wochenschr 1982; 60: 1006-9.
25. Morray JP, Geiduschek JM, Ramamoorthy C, et al. Anesthesia-related cardiac arrest in children: initial findings of the Pediatric Perioperative Cardiac Arrest (POCA) Registry. Anesthesiology 2000; 93: 6-14.
26. Wu KH, Rau RH, Lin CF, et al. Cardiac arrest during anesthesia in a teaching hospital: a 4 years survey. Int Surg 1997; 82: 254-6.
27. Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programs. Health Serv Res 1972; 7: 118-33.
28. Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socio-Economic Planning Sciences 1976; 10: 129-36.
29. Torrance GW, Feeny DH, Furlong WJ, et al. Multiattribute utility function for a comprehensive health status classification syste. Health Utilities Index Mark 2. Med Care 1996; 34: 702-22.
30. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989; 5: 559-75.
31. Naimark D, Naglie G, Detsky AS. The meaning of life expectancy: what is a clinically significant gain? J Gen Intern Med 1994; 9: 702-7.
32. Hlatky MA. Is renal biopsy necessary in adults with nephrotic syndrome. Lancet 1982; 2: 1264-8.
33. Krahn MD, Mahoney JE, Eckman MH, et al. Screening for prostate cancer. A decision analytic view. JAMA 1994; 272: 773-80.
34. Ransohoff DF, Gracie WA, Wolfenson LB, et al. Prophylactic cholecystectomy or expectant management for silent gallstones: a decision analysis to assess survival. Ann Intern Med 1983; 99: 199-204.
35. Hollenberg JP, Subak LL, Ferry Jr., JJ, et al. Cost-effectiveness of splenectomy versus intravenous gamma globulin in treatment of chronic immune thrombocytopenic purpura in childhood. J Pediatr 1988; 112: 530-9.
36. Boyle MH, Torrance GW, Sinclair JC, et al. Economic evaluation of neonatal intensive care of very-low-birth-weight infants. N Engl J Med 1983; 308: 1330-7.
37. Rosenfeld SJ, Kimball J, Vining D, et al. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 1995; 85: 3058-65.
38. Doney K, Leisenring W, Storb R, et al. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Ann Intern Med 1997; 126: 107-15.
39. Gaynon PS, Lustig RH. The use of glucocorticoids in acute lymphoblastic leukemia of childhood. Molecular, cellular, and clinical considerations. J Pediatr Hematol Oncol 1995; 17: 1-12.
40. Henze G, Fengler R, Hartmann R, et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 1991; 78: 1166-72.